Wells Fargo & Company Outlook Therapeutics, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.22 - $0.66 $2,132 - $6,397	9,693 Added 31.44%	40,527 $15,000
Q3 2023 Nov 13, 2023	SELL	$0.2 - $1.78 $34,479 - $306,868	-172,398 Reduced 84.83%	30,834 $6,000
Q2 2023 Aug 15, 2023	BUY	$1.02 - $1.89 $35,531 - $65,838	34,835 Added 20.69%	203,232 $353,000
Q1 2023 May 12, 2023	BUY	$1.0 - $1.35 $29,667 - $40,050	29,667 Added 21.38%	168,397 $183,000
Q4 2022 Feb 13, 2023	SELL	$0.87 - $1.33 $1,826 - $2,791	-2,099 Reduced 1.49%	138,730 $149,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $13,045 - $16,115	12,790 Added 9.99%	140,829 $172,000
Q2 2022 Aug 12, 2022	BUY	$0.91 - $2.01 $28,315 - $62,543	31,116 Added 32.1%	128,039 $130,000
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $22,890 - $38,088	18,763 Added 24.01%	96,923 $173,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $90,333 - $158,617	71,129 Added 1011.65%	78,160 $107,000
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $14,840 - $19,320	7,000 Added 22580.65%	7,031 $15,000
Q2 2021 Aug 16, 2021	SELL	$1.78 - $2.76 $1,041 - $1,614	-585 Reduced 94.97%	31 $0
Q1 2021 May 13, 2021	BUY	$0.94 - $3.31 $208 - $734	222 Added 56.35%	616 $1,000
Q4 2020 Feb 09, 2021	BUY	$0.7 - $1.58 $35 - $80	51 Added 14.87%	394 $0
Q3 2020 Nov 05, 2020	BUY	$0.61 - $1.6 $80 - $211	132 Added 62.56%	343 $0
Q2 2020 Aug 13, 2020	BUY	$0.56 - $1.41 $39 - $98	70 Added 49.65%	211 $0
Q1 2020 May 14, 2020	BUY	$0.51 - $1.08 $71 - $152	141 New	141 $0

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $536M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.